COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness

Kherabi, Yousra; Launay, Odile; Ngũyen, Liem Binh Luong

doi:10.3390/v14102086

Cited by 15 publications

(13 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Moreover, the Omicron COVID-19 variant, which is now spreading in China, has been reported to have prominent immune evasion and enhanced transmissibility. 25,26 Therefore, this can explain why the vaccination did not prevent COVID-19 in PD patients.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and outcomes in Chinese peritoneal dialysis patients

Liao,

Zhou,

et al. 2024

Perit Dial Int

View full text Add to dashboard Cite

Background: Reports on COVID-19 in peritoneal dialysis (PD) patients are scarce in China. This study aimed to describe the characteristics and outcomes of PD patients with COVID-19 after China abandoned the ‘zero-COVID’ policy. Methods: This single-centre retrospective study included patients receiving PD who underwent testing for COVID-19 infections between 7 December 2022 and 7 January 2023. Outcomes of interest included factors associated with positive COVID-19 testing result and clinical outcomes including COVID-19-related hospitalisation and severe COVID-19, which were analysed using logistic regression analyses. Results: A total of 349 PD patients (male 53.6%, age 49 ± 13 years old) were included, and 235 patients (67.3%) were infected. There were no significant differences between COVID-19 and non-COVID-19 patients other than higher proportion of vaccinated patients and slow transporters in the patients who tested positive for COVID-19 (44.7% vs. 28.1%, p = 0.003; 8.7% vs. 1.8%, p = 0.03, respectively). Multivariate analysis showed COVID-19 was associated with vaccination (odds ratio (OR): 1.71, 95% confidence interval (CI): 1.02–2.86) and slow transport type (compared with average transport type, OR: 4.52, 95% CI: 1.01–20.21). Among the patients with infection, 38 (16.2%) patients were hospitalised, 18 (7.7%) patients had severe disease and 9 (3.8%) patients died. In multivariate logistic analysis, both age (OR: 1.04, 95% CI: 1.01–1.07; OR: 1.06, 95% CI: 1.02–1.11) and hyponatremia (OR: 5.44, 95% CI: 1.63–18.13; OR: 6.50, 95% CI: 1.77–23.85) were independent risk factors for COVID-19-related hospitalisation and severe disease. Conclusions: Although vaccinated patients were more likely to have tested positive for COVID-19 infection, they appeared to have less severe infection and less need for hospitalisation. Patients who were older with a history of hyponatremia were more likely to experience adverse outcomes from COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 and outcomes in Chinese peritoneal dialysis patients

Liao,

Zhou,

et al. 2024

Perit Dial Int

View full text Add to dashboard Cite

show abstract

“…In addition, the rapid development and dissemination of COVID-19 vaccines marked a watershed moment in the global response to the virus [ 2 ]. These vaccines, licensed for use in emergencies on the basis of limited clinical data, owe much of their success to the critical role played by real-world data, which are critical to understanding vaccine efficacy and safety in diverse populations [ 3 ]. Efforts to address these challenges and establish frameworks for responsible data sharing are crucial.…”

Section: Introductionmentioning

confidence: 99%

A One Health Platform for Future Epidemic Preparedness

Branda,

Scarpa,

Petrosillo

et al. 2024

Infectious Disease Reports

View full text Add to dashboard Cite

Here, we introduce the EpiConnect Intelligence Platform (ECIP), a platform facilitating rapid, transparent data sharing and analysis to support researchers and public health officials in Europe, with a focus on Italy. ECIP provides reliable, concise, machine-readable data to aid in epidemiological understanding, standardize case characteristics, and estimate key parameters. The platform adheres to FAIR (findable, accessible, interoperable, reusable) principles, offering easily accessible and downloadable datasets for researchers’ endeavors. Future enhancements include involving national public health authorities, expanding data streams, and fostering collaboration between experts and users for improved epidemic risk monitoring. Shared standards among diverse surveillance systems are advocated to achieve common strategic goals, emphasizing the need for forward-looking policies to empower professionals to analyze disease dynamics in the context of evolving health crises. The recent emergencies underscore the importance of collective efforts towards shared strategic goals, highlighting the necessity for coordinated action to address mutual concerns affecting everyone’s lives.

show abstract

“…However, its effectiveness against severe illness and death related to the Omicron variant remained much better. 18 …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

Zhang

Wang²,

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against the Omicron BA.2.2 variant remains scarce. A case–control study was conducted to estimate the vaccine effectiveness (VE) of COVID-19 vaccines marketed in China (inactivated vaccines, an Ad5-nCoV vaccine, and a recombinant protein vaccine). There were 414 cases infected with SARS-CoV-2 and 828 close contacts whose test results were consecutively negative as controls during the outbreak of the Omicron variant in Lu’an City, Anhui Province, China, in April 2022. The overall adjusted VE against Omicron BA.2.2 variant infection in the vaccinated group with any COVID-19 vaccine was 35.0% (95% CI: −9.1–61.3%), whereas the adjusted VE for booster vaccination was 51.6% (95% CI: 15.2–72.4%). Subgroup analysis showed that the overall adjusted VE of the Ad5-nCoV vaccine (65.8%, 95% CI: 12.8–86.6%) during the outbreak while any dose of inactivated vaccines and recombinant protein vaccine offered no protection. The adjusted VE of three-dose inactivated vaccines was 48.0% (95% CI: 8.0–70.6%), and the two-dose Ad5-nCoV vaccine was 62.9% (95% CI: 1.8–86%). There is no protection from a three-dose recombinant protein vaccine. COVID-19 vaccines offered 46.8% (95% CI: 9.5–68.7%) protection from infection within six months. There were statistically significant differences between the VEs of heterologous booster (VE = 76.4%, 95% CI: 14.3–93.5%) and homologous booster vaccination (VE = 51.8%, 95% CI: 9.6–74.3%) ( P = .036). Booster vaccination of COVID-19 vaccines offered more protection than full vaccination. A booster vaccination campaign for a booster dose after three doses of a recombinant protein vaccine must be urgently conducted.

show abstract

COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness

Cited by 15 publications

References 68 publications

COVID-19 and outcomes in Chinese peritoneal dialysis patients

COVID-19 and outcomes in Chinese peritoneal dialysis patients

A One Health Platform for Future Epidemic Preparedness

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

Contact Info

Product

Resources

About